Biotech sees big money from corporate players

Corporations see some big advantages in investing in their own fields. A new report from the National Venture Capital Association finds that corporations funneled $1.3 billion in venture funds to private companies in the first six months--and biotechnology was one of the leading industries to attract this money. Corporate venture capital groups took a piece of the action in slightly more than one in five venture deals in the first half of this year, says the association, using money as the best tool for buddying up with companies that are developing new technologies.

"If corporate venture investment continues at this pace, we could see all-time record levels in the near future," said National Venture Capital Association President Mark Heesen.

- see the release for more
- read the report from the Pacific Business News

Related Articles:
Pfizer to invest $50M in biotech start-ups. Report
The 10 Commandments of biotech investing. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.